CVX Vaccine Codes
CDC Immunization & Vaccine Code Set
The CDC's National Center of Immunization and Respiratory Diseases (NCIRD) developed and maintains the CVX (vaccine administered) code set. CVX codes for inactive vaccines allow transmission of historical immunization records. When a MVX (manufacturer) code is paired with a CVX (vaccine administered) code, the specific trade named vaccine may be indicated.
Use ICD-10-CM code Z23 Encounter for immunization to. CPT® codes are specific to the type of vaccine.
CVX codes by group
311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | Active |
312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | Active |
310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | Active |
308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | Active |
309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | Active |
313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | Active |
516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | Non-US |
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | Non-US |
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | Non-US |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | Non-US |
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | Non-US |
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | Non-US |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | Non-US |
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | Non-US |
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | Non-US |
500 | COVID-19 Non-US Vaccine, Product Unknown | Non-US |
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) | Non-US |
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | Non-US |
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | Non-US |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | Non-US |
210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | Non-US |
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | Non-US |
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | Non-US |
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | Non-US |
514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | Non-US |
513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | Non-US |
517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | Non-US |
515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | Non-US |
512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | Non-US |
212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | Inactive |
230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | Inactive |
301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | Inactive |
302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | Inactive |
300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | Inactive |
229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | Inactive |
218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | Inactive |
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Inactive |
219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | Inactive |
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Inactive |
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Inactive |
221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | Inactive |
228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | Inactive |
227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | Inactive |
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | Inactive |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | Inactive |
226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | Never Active |
225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | Never Active |
205 | Influenza vaccine, quadrivalent, adjuvanted | Active |
135 | Influenza, high dose seasonal | Active |
197 | influenza, high-dose, quadrivalent | Active |
171 | Influenza, injectable, MDCK, preservative free, quadrivalent | Active |
186 | Influenza, injectable, MDCK, quadrivalent, preservative | Active |
158 | influenza, injectable, quadrivalent | Active |
150 | influenza, injectable, quadrivalent, preservative free | Active |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | Active |
149 | influenza, live, intranasal, quadrivalent | Active |
155 | influenza, recombinant, injectable, preservative free | Active |
185 | influenza, recombinant, quadrivalent,injectable, preservative free | Active |
141 | Influenza, seasonal, injectable | Active |
231 | influenza, Southern Hemisphere, high-dose, quadrivalent | Active |
200 | influenza, Southern Hemisphere, pediatric, preservative free | Active |
201 | influenza, Southern Hemisphere, preservative free | Active |
202 | influenza, Southern Hemisphere, quadrivalent, with preservative | Active |
168 | influenza, trivalent, adjuvanted | Active |
151 | influenza nasal, unspecified formulation | Inactive |
153 | Influenza, injectable, MDCK, preservative free | Inactive |
166 | influenza, intradermal, quadrivalent, preservative free | Inactive |
111 | influenza, live, intranasal | Inactive |
140 | Influenza, seasonal, injectable, preservative free | Inactive |
144 | influenza, seasonal, intradermal, preservative free | Inactive |
194 | Influenza, Southern Hemisphere | Inactive |
15 | influenza, split (incl. purified surface antigen) | Inactive |
88 | influenza, unspecified formulation | Inactive |
16 | influenza, whole | Inactive |
146 | DTaP,IPV,Hib,HepB | Active |
110 | DTaP-Hep B-IPV | Active |
104 | Hep A-Hep B | Active |
08 | Hep B, adolescent or pediatric | Active |
43 | Hep B, adult | Active |
44 | Hep B, dialysis | Active |
220 | HepB recombinant, 3-antigen, Al(OH)3 | Active |
189 | HepB-CpG | Active |
102 | DTP-Hib-Hep B | Non-US |
193 | Hep A-Hep B, pediatric/adolescent | Non-US |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive |
42 | Hep B, adolescent/high risk infant | Inactive |
45 | Hep B, unspecified formulation | Inactive |
51 | Hib-Hep B | Inactive |
305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | Active |
306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | Active |
307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | Active |
303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | Active |
315 | Respiratory syncytial virus (RSV) MAB, unspecified | Inactive |
314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Inactive |
304 | Respiratory syncytial virus (RSV), unspecified | Inactive |
09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | Active |
113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | Active |
196 | Td, adsorbed, preservative free, adult use, Lf unspecified | Active |
195 | DT, IPV adsorbed | Non-US |
138 | Td (adult) | Inactive |
139 | Td(adult) unspecified formulation | Inactive |
35 | tetanus toxoid, adsorbed | Inactive |
181 | anthrax immune globulin | Active |
801 | AS03 Adjuvant | Active |
27 | botulinum antitoxin | Active |
29 | CMVIG | Active |
12 | diphtheria antitoxin | Active |
30 | HBIG | Active |
86 | IG | Active |
87 | IGIV | Active |
157 | Rho(D) -IG IM | Active |
156 | Rho(D)-IG | Active |
34 | RIG | Active |
93 | RSV-MAb | Active |
13 | TIG | Active |
79 | vaccinia immune globulin | Active |
36 | VZIG | Active |
198 | DTP-hepB-Hib Pentavalent Non-US | Non-US |
169 | Hep A, live attenuated | Non-US |
191 | meningococcal A polysaccharide (non-US) | Non-US |
192 | meningococcal AC polysaccharide (non-US) | Non-US |
179 | OPV ,monovalent, unspecified | Non-US |
178 | OPV bivalent | Non-US |
190 | Typhoid conjugate vaccine (TCV) | Non-US |
54 | adenovirus, type 4 | Inactive |
14 | IG, unspecified formulation | Inactive |
167 | meningococcal, unknown serogroups | Inactive |
998 | no vaccine administered | Inactive |
182 | OPV, Unspecified | Inactive |
69 | parainfluenza-3 | Inactive |
11 | pertussis | Inactive |
99 | RESERVED - do not use | Inactive |
159 | Rho(D) - Unspecified formulation | Inactive |
71 | RSV-IGIV | Inactive |
76 | Staphylococcus bacterio lysate | Inactive |
180 | tetanus immune globulin | Inactive |
142 | tetanus toxoid, not adsorbed | Inactive |
112 | tetanus toxoid, unspecified formulation | Inactive |
98 | TST, unspecified formulation | Inactive |
95 | TST-OT tine test | Inactive |
96 | TST-PPD intradermal | Inactive |
97 | TST-PPD tine test | Inactive |
78 | tularemia vaccine | Inactive |
131 | typhus, historical | Inactive |
999 | unknown | Inactive |
57 | hantavirus | Never Active |
154 | Hep A, IG | Never Active |
58 | Hep C | Never Active |
59 | Hep E | Never Active |
60 | herpes simplex 2 | Never Active |
61 | HIV | Never Active |
63 | Junin virus | Never Active |
64 | leishmaniasis | Never Active |
65 | leprosy | Never Active |
67 | malaria | Never Active |
68 | melanoma | Never Active |
70 | Q fever | Never Active |
72 | rheumatic fever | Never Active |
73 | Rift Valley fever | Never Active |
145 | RSV-MAb (new) | Never Active |
117 | VZIG (IND) | Never Active |
CVX codes by manufacturer
current/active
Parent Company of MedImmune
manufacturer of national stockpile smallpox vaccine Jynneos
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (COVAXIN)
Non-US COVID-19 vaccine manufacturer, WHO Authorized (CONVIDECIA) on 5/19/2022
Companies include Emergent Product Development Gaithersburg Inc. and former Emergent BioDefense Operations Lansing and Michigan Biologic Products Institute
Emergent Biosolutions acquired PaxVax 8/2021, US Vaccines starting to label under Emergent Travel Health Inc.
includes SmithKline Beecham and Glaxo Wellcome
801 | AS03 Adjuvant | Inactive | AS03 adjuvant |
20 | DTaP | Active | INFANRIX |
110 | DTaP-Hep B-IPV | Active | PEDIARIX |
130 | DTaP-IPV | Active | KINRIX |
52 | Hep A, adult | Active | HAVRIX-ADULT |
83 | Hep A, ped/adol, 2 dose | Active | HAVRIX-PEDS |
104 | Hep A-Hep B | Active | TWINRIX |
08 | Hep B, adolescent or pediatric | Active | ENGERIX B-PEDS |
43 | Hep B, adult | Active | ENGERIX-B-ADULT |
48 | Hib (PRP-T) | Active | HIBERIX |
118 | HPV, bivalent | Inactive | CERVARIX |
160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | Inactive | Influenza A monovalent (H5N1), ADJUVANTED-2013 |
150 | influenza, injectable, quadrivalent, preservative free | Active | Fluarix, quadrivalent, preservative free |
140 | Influenza, seasonal, injectable, preservative free | Inactive | FLUARIX |
163 | meningococcal B, OMV | Active | Bexsero |
148 | Meningococcal C/Y-HIB PRP | Inactive | MENHIBRIX |
136 | Meningococcal MCV4O | Active | Menveo |
03 | MMR | Active | Priorix |
176 | Rabies - IM fibroblast culture | Active | RABAVERT |
119 | rotavirus, monovalent | Active | ROTARIX |
303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | Active | Arexvy |
115 | Tdap | Active | BOOSTRIX |
187 | zoster recombinant | Active | SHINGRIX |
Grifols is a labeler and not a manufacturer.
Part of GlaxoSmithKline
160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | Active | Influenza A (H5N1) -2013 |
158 | influenza, injectable, quadrivalent | Active | Flulaval quadrivalent |
150 | influenza, injectable, quadrivalent, preservative free | Active | Flulaval, quadrivalent, preservative free |
141 | Influenza, seasonal, injectable | Active | FLULAVAL |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Flulaval, preservative free |
Division of Johnson and Johnson, manufacturer of Covid-19 vaccine
formerly Massachusetts Public Health Biologic Laboratories
Non-US COVID-19 vaccine manufacturer Cofivenz vaccine recognized by ACIP
Subsidiary of AstraZeneca
19 | BCG | Active | TICE BCG |
204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | Active | ERVEBO (Ebola Zaire Vaccine, Live) |
52 | Hep A, adult | Active | VAQTA-ADULT |
83 | Hep A, ped/adol, 2 dose | Active | VAQTA-PEDS |
08 | Hep B, adolescent or pediatric | Active | RECOMBIVAX-PEDS |
43 | Hep B, adult | Active | RECOMBIVAX-ADULT |
44 | Hep B, dialysis | Active | RECOMBIVAX-DIALYSIS |
49 | Hib (PRP-OMP) | Active | PEDVAXHIB |
51 | Hib-Hep B | Inactive | COMVAX |
62 | HPV, quadrivalent | Inactive | GARDASIL |
165 | HPV9 | Active | Gardasil 9 |
05 | measles | Inactive | ATTENUVAX |
03 | MMR | Active | M-M-R II |
94 | MMRV | Active | PROQUAD |
215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | Active | VAXNEUVANCE |
33 | pneumococcal polysaccharide PPV23 | Active | PNEUMOVAX 23 |
116 | rotavirus, pentavalent | Active | ROTATEQ |
06 | rubella | Inactive | MERUVAX II |
21 | varicella | Active | VARIVAX |
121 | zoster live | Active | ZOSTAVAX |
New vaccine manufacturer effective 11/1/2020
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | Active | Moderna COVID-19 Bivalent, Original + BA.1 (Non-US Tradename Spikevax Bivalent) |
230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | Active | Moderna COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename Spikevax Bivalent) |
229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | Active | Moderna COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename Spikevax Bivalent) |
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Active | Moderna COVID-19 Vaccine (non-US Spikevax) |
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | Active | SPIKEVAX |
311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | Active | Moderna COVID-19 Vaccine (US only) |
312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | Active | SPIKEVAX |
221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | Active | Moderna COVID-19 Vaccine (non-US Spikevax) |
228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | Active | Moderna COVID-19 Vaccine (non-US Spikevax) |
227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | Active | Moderna COVID-19 Vaccine (non-US Spikevax) |
US Based - Joint manufacturing partnership, initial vaccine Vaxelis 10/2020
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | Active | Novavax COVID-19 Vaccine (Non-US Tradenames NUVAXOVID, COVOVAX) |
313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | Active | Novavax COVID-19 Vaccine, Adjuvanted (US Only) |
COVID-19 vaccine in co-development with BioNTech. Pfizer includes Wyeth-Lederle Vaccines and Pediatrics, Wyeth Laboratories, Lederle Laboratories, and Praxis Biologics
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | Active | Pfizer COVID-19 Bivalent, Original + BA.1 (Non-US Tradename COMIRNATY Bivalent) |
301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | Active | Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) |
302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | Active | Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) |
300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | Active | Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) |
218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | Active | Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) |
219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | Active | Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) |
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Active | COMIRNATY |
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | Active | Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) |
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Active | COMIRNATY |
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | Active | Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) |
310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | Active | Pfizer-BioNTech COVID-19 Vaccine (US Only) |
308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | Active | Pfizer-BioNTech COVID-19 Vaccine (US Only) |
309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | Active | COMIRNATY |
162 | meningococcal B, recombinant | Active | Trumenba |
316 | meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | Active | PENBRAYA |
133 | Pneumococcal conjugate PCV 13 | Active | PREVNAR 13 |
216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | Active | PREVNAR 20 |
305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | Active | ABRYSVO |
223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | Active | TICOVAC |
224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | Active | TICOVAC |
Acquired by Sanofi Pasteur (08/28/2017), continues to manufacture vaccines distributed by Sanofi
Formerly Aventis Pasteur, Pasteur Merieux Connaught; includes Connaught Laboratories and Pasteur Merieux. Acquired ACAMBIS; Acquired Protein Sciences (8/28/2017)
226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | Active | Sanofi COVID-19 |
225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | Active | Sanofi COVID-19 |
56 | dengue fever tetravalent | Active | DENGVAXIA |
28 | DT (pediatric) | Active | DT(GENERIC) |
20 | DTaP | Inactive | TRIPEDIA |
106 | DTaP, 5 pertussis antigens | Active | DAPTACEL |
50 | DTaP-Hib | Inactive | TRIHIBIT |
120 | DTaP-Hib-IPV | Active | PENTACEL |
130 | DTaP-IPV | Active | Quadracel |
48 | Hib (PRP-T) | Active | ACTHIB |
135 | Influenza, high dose seasonal | Active | FLUZONE-HIGH DOSE |
197 | influenza, high-dose, quadrivalent | Active | FLUZONE High-Dose Quadrivalent |
158 | influenza, injectable, quadrivalent | Active | Fluzone, Quadrivalent |
150 | influenza, injectable, quadrivalent, preservative free | Active | Fluzone, quadrivalent, preservative free |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | Active | Fluzone Quadrivalent, pediatric |
166 | influenza, intradermal, quadrivalent, preservative free | Inactive | Fluzone Quad Intradermal |
185 | influenza, recombinant, quadrivalent,injectable, preservative free | Active | Flublok quadrivalent |
141 | Influenza, seasonal, injectable | Active | FLUZONE |
140 | Influenza, seasonal, injectable, preservative free | Inactive | FLUZONE-PRESERVATIVE FREE |
144 | influenza, seasonal, intradermal, preservative free | Inactive | Fluzone, intradermal |
231 | influenza, Southern Hemisphere, high-dose, quadrivalent | Active | FLUZONE High-Dose Quadrivalent Southern Hemisphere |
200 | influenza, Southern Hemisphere, pediatric, preservative free | Active | FLUZONE Quadrivalent Southern Hemisphere, Pediatric |
201 | influenza, Southern Hemisphere, preservative free | Active | FLUZONE Quadrivalent Southern Hemisphere |
202 | influenza, Southern Hemisphere, quadrivalent, with preservative | Active | FLUZONE Quadrivalent Southern Hemisphere |
10 | IPV | Active | IPOL |
203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | Active | MenQuadfi |
114 | meningococcal MCV4P | Active | MENACTRA |
32 | meningococcal MPSV4 | Inactive | MENOMUNE |
127 | Novel influenza-H1N1-09 | Inactive | Novel influenza-H1N1-09 |
126 | Novel influenza-H1N1-09, preservative-free | Inactive | Novel influenza-H1N1-09, preservative-free |
175 | Rabies - IM Diploid cell culture | Active | IMOVAX |
40 | rabies, intradermal injection | Inactive | IMOVAX ID |
18 | rabies, intramuscular injection | Inactive | Imovax |
306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | Active | BEYFORTUS |
307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | Active | BEYFORTUS |
113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | Inactive | DECAVAC |
113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | Active | Tenivac |
115 | Tdap | Active | ADACEL |
35 | tetanus toxoid, adsorbed | Inactive | TETANUS TOXOID (GENERIC) |
101 | typhoid, ViCPs | Active | TYPHIM VI |
37 | yellow fever | Active | YF-VAX |
183 | Yellow fever vaccine - alt | Active | Stamaril |
Seqirus acquired the flu vaccines from Novartis. It also includes the CSL vaccines.
205 | Influenza vaccine, quadrivalent, adjuvanted | Active | FLUAD Quadrivalent |
171 | Influenza, injectable, MDCK, preservative free, quadrivalent | Active | flucelvax, quadrivalent, preservative free |
186 | Influenza, injectable, MDCK, quadrivalent, preservative | Active | Flucelvax, quadrivalent, with preservative |
158 | influenza, injectable, quadrivalent | Active | Afluria, quadrivalent |
150 | influenza, injectable, quadrivalent, preservative free | Active | Afluria quadrivalent preservative free |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric | Active | Afluria quadrivalent, preservative free, pediatric |
141 | Influenza, seasonal, injectable | Active | Afluria |
141 | Influenza, seasonal, injectable | Active | Fluvirin |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Afluria, preservative free |
140 | Influenza, seasonal, injectable, preservative free | Inactive | Fluvirin preservative free |
168 | influenza, trivalent, adjuvanted | Active | Fluad |
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized
Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (Sinovac, CoronaVac)
BARR Laboratories merged with TEVA in 2007. The MVX for Barr was retired in 2011, TEVA continues to produce the former BARR vaccines
Distributes through Intercell in the US
New Vaccine Manufacturer added 1/2022
acquired by Pfizer 10/15/2009
Non-US
173 | cholera, BivWC | Non-US | n/a |
172 | cholera, WC-rBS | Non-US | n/a |
516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | Non-US | n/a |
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | Non-US | n/a |
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | Non-US | n/a |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | Non-US | n/a |
500 | COVID-19 Non-US Vaccine, Product Unknown | Non-US | n/a |
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) | Non-US | n/a |
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | Non-US | n/a |
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | Non-US | n/a |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | Non-US | n/a |
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | Non-US | n/a |
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | Non-US | n/a |
195 | DT, IPV adsorbed | Non-US | n/a |
170 | DTAP/IPV/HIB - non-US | Non-US | n/a |
198 | DTP-hepB-Hib Pentavalent Non-US | Non-US | n/a |
102 | DTP-Hib-Hep B | Non-US | n/a |
169 | Hep A, live attenuated | Non-US | n/a |
193 | Hep A-Hep B, pediatric/adolescent | Non-US | n/a |
191 | meningococcal A polysaccharide (non-US) | Non-US | n/a |
192 | meningococcal AC polysaccharide (non-US) | Non-US | n/a |
179 | OPV ,monovalent, unspecified | Non-US | n/a |
178 | OPV bivalent | Non-US | n/a |
177 | PCV10 | Non-US | n/a |
514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | Non-US | n/a |
513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | Non-US | n/a |
517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | Non-US | n/a |
515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | Non-US | n/a |
77 | Tick-borne encephalitis vaccine (non-US) | Non-US | n/a |
190 | Typhoid conjugate vaccine (TCV) | Non-US | n/a |
Inactive
acquired by sanofi in sept 2008
Subsidiary of Teva Pharmaceuticals
acquired Berna, now a J & J company
Novartis has sold its flu vaccines to Seqirus and other vaccines to GlaxoSmithKline. While Novartis vaccines may still be in circulation, its status is set to not active.
153 | Influenza, injectable, MDCK, preservative free | Inactive | Flucelvax |
141 | Influenza, seasonal, injectable | Active | FLUVIRIN |
140 | Influenza, seasonal, injectable, preservative free | Inactive | AGRIFLU |
140 | Influenza, seasonal, injectable, preservative free | Inactive | FLUVIRIN-PRESERVATIVE FREE |
168 | influenza, trivalent, adjuvanted | Active | Fluad |
163 | meningococcal B, OMV | Active | Bexsero |
136 | Meningococcal MCV4O | Active | MENVEO |
127 | Novel influenza-H1N1-09 | Inactive | Novel influenza-H1N1-09 |
126 | Novel influenza-H1N1-09, preservative-free | Inactive | Novel influenza-H1N1-09, preservative-free |
176 | Rabies - IM fibroblast culture | Inactive | RABAVERT |
54 | adenovirus, type 4 | Inactive | n/a |
55 | adenovirus, type 7 | Inactive | n/a |
82 | adenovirus, unspecified formulation | Inactive | n/a |
19 | BCG | Inactive | MYCOBAX |
26 | cholera, unspecified formulation | Inactive | n/a |
20 | DTaP | Inactive | ACEL-IMUNE |
20 | DTaP | Inactive | CERTIVA |
107 | DTaP, unspecified formulation | Inactive | n/a |
132 | DTaP-IPV-HIB-HEP B, historical | Inactive | n/a |
01 | DTP | Inactive | n/a |
22 | DTP-Hib | Inactive | TETRAMUNE |
214 | Ebola, unspecified | Inactive | n/a |
84 | Hep A, ped/adol, 3 dose | Inactive | n/a |
31 | Hep A, pediatric, unspecified formulation | Inactive | n/a |
85 | Hep A, unspecified formulation | Inactive | n/a |
42 | Hep B, adolescent/high risk infant | Inactive | n/a |
45 | Hep B, unspecified formulation | Inactive | n/a |
47 | Hib (HbOC) | Inactive | HIBTITER |
46 | Hib (PRP-D) | Inactive | PROHIBIT |
48 | Hib (PRP-T) | Inactive | OMNIHIB |
17 | Hib, unspecified formulation | Inactive | n/a |
137 | HPV, unspecified formulation | Inactive | n/a |
14 | IG, unspecified formulation | Inactive | n/a |
151 | influenza nasal, unspecified formulation | Inactive | n/a |
123 | influenza, H5N1-1203 | Inactive | n/a |
194 | Influenza, Southern Hemisphere | Inactive | n/a |
15 | influenza, split (incl. purified surface antigen) | Inactive | n/a |
88 | influenza, unspecified formulation | Inactive | n/a |
16 | influenza, whole | Inactive | n/a |
129 | Japanese Encephalitis, unspecified formulation | Inactive | n/a |
66 | Lyme disease | Inactive | n/a |
04 | M/R | Inactive | n/a |
108 | meningococcal ACWY, unspecified formulation | Inactive | n/a |
164 | meningococcal B, unspecified | Inactive | n/a |
103 | meningococcal C conjugate | Inactive | n/a |
147 | meningococcal MCV4, unspecified formulation | Inactive | n/a |
167 | meningococcal, unknown serogroups | Inactive | n/a |
07 | mumps | Inactive | MUMPSVAX |
998 | no vaccine administered | Inactive | n/a |
128 | Novel Influenza-H1N1-09, all formulations | Inactive | n/a |
02 | OPV | Inactive | ORIMUNE |
182 | OPV, Unspecified | Inactive | n/a |
69 | parainfluenza-3 | Inactive | n/a |
11 | pertussis | Inactive | n/a |
23 | plague | Inactive | n/a |
152 | Pneumococcal Conjugate, unspecified formulation | Inactive | n/a |
109 | pneumococcal, unspecified formulation | Inactive | n/a |
89 | polio, unspecified formulation | Inactive | n/a |
90 | rabies, unspecified formulation | Inactive | n/a |
99 | RESERVED - do not use | Inactive | n/a |
315 | Respiratory syncytial virus (RSV) MAB, unspecified | Inactive | n/a |
314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Inactive | n/a |
304 | Respiratory syncytial virus (RSV), unspecified | Inactive | n/a |
159 | Rho(D) - Unspecified formulation | Inactive | n/a |
74 | rotavirus, tetravalent | Inactive | n/a |
122 | rotavirus, unspecified formulation | Inactive | n/a |
71 | RSV-IGIV | Inactive | n/a |
38 | rubella/mumps | Inactive | BIAVAX II |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | Inactive | n/a |
76 | Staphylococcus bacterio lysate | Inactive | n/a |
138 | Td (adult) | Inactive | n/a |
139 | Td(adult) unspecified formulation | Inactive | n/a |
180 | tetanus immune globulin | Inactive | n/a |
142 | tetanus toxoid, not adsorbed | Inactive | n/a |
112 | tetanus toxoid, unspecified formulation | Inactive | n/a |
222 | Tick-borne encephalitis, unspecified | Inactive | n/a |
98 | TST, unspecified formulation | Inactive | n/a |
95 | TST-OT tine test | Inactive | n/a |
96 | TST-PPD intradermal | Inactive | n/a |
97 | TST-PPD tine test | Inactive | n/a |
78 | tularemia vaccine | Inactive | n/a |
41 | typhoid, parenteral | Inactive | n/a |
53 | typhoid, parenteral, AKD (U.S. military) | Inactive | TYPHOID-AKD |
91 | typhoid, unspecified formulation | Inactive | n/a |
131 | typhus, historical | Inactive | n/a |
999 | unknown | Inactive | n/a |
75 | vaccinia (smallpox) | Inactive | DRYVAX |
105 | vaccinia (smallpox) diluted | Inactive | n/a |
81 | VEE, inactivated | Inactive | n/a |
80 | VEE, live | Inactive | n/a |
92 | VEE, unspecified formulation | Inactive | n/a |
184 | Yellow fever, unspecified formulation | Inactive | n/a |
188 | zoster, unspecified formulation | Inactive | n/a |
Never Active
About CVX Codes
In 1999, the CDC published an implementation guide for messaging immunization histories. Two value sets were defined that allowed specification of the vaccine used at the vaccine administration level. The CVX code is a numeric string, which identifies the type of vaccine
product used. The MVX code is an alphabetic string that identifies the manufacturer of that vaccine. Taken together, the immunization can be resolved to a trade name (the proprietary name of the product).
For example, a CVX code of 43 represents Hepatitis B, adult formulation. There are 2 manufacturers of this vaccine, GlaxoSmithKline (MVX = SKB) and Merck (MVX = MSD). An immunization using Recombivax, a Hepatitis B vaccine manufactured by Merck, would have a CVX of 43 and an MVX of MSD.
When these codes were developed, they were designed to accommodate reporting of vaccine histories when the manufacturer and trade name are not known. This is because a client often had a shot card listing the vaccinations received, but with only a date and vaccine group listed. If the manufacturer and formulation were not known, then the Hepatitis B vaccine administered would be coded with a CVX of 45 (Hepatitis B, not otherwise specified).
Other codes exist that are associated with the coding of a vaccine. These include: RxNorm, NDC, and CPT®. RxNorm, a standardized nomenclature for clinical drugs and drug delivery devices, is produced by the National Library of Medicine (NLM). In RxNorm, the name of a clinical drug combines its ingredients, strengths, and/or form.
Typically, there are a number of factors that determine which vaccine will have the same or a different CVX code:
- the formulation
- the concentration
- the manufacturing process (egg culture vs. cell culture)
- the route of administration
MVX Codes - Manufacturers of Vaccines
The MVX is an alphabetic string, which represents the manufacturer of a vaccine. When MVX code is paired with a CVX (vaccine administered) code, the specific trade named vaccine may be indicated. The MVX code reflects the manufacturer of the specific instance of the vaccine. For example, Pfizer (MVX = PFR) acquired Wyeth (MVX = WAL). Prevnar is a vaccine that was manufactured by Wyeth. Immunizations of Prevnar that were manufactured by Wyeth continue to use the MVX of WAL. Prevnar that is now manufactured by Pfizer will have an MVX of PFR. Existing records will not be changed.
source: https://www.cdc.gov/vaccines/programs/iis/downloads/business-rules.pdf
Thank you for choosing Find-A-Code, please Sign In to remove ads.